Showdown, Though Not Quite at the OK Corral

Carl Icahn is taking another swing at Genzyme; he is going after four seats on Genzyme’s nine-member board — for himself and for three associates, reports the New York Times. Icahn has not said what his plans might be for Genzyme, though the Times notes that when Icahn wins seats on boards, chief executive officers tend to leave and Genzyme’s Henri Termeer isn’t expected to go without a fight. “I’m sure Henri will fight,” says former Genzyme director Constantine Anagnostopoulos. “But he will not fight if his fighting is detrimental to Genzyme. Genzyme is Henri’s baby.” In a statement, Termeer says that Genzyme would “welcome a constructive dialogue with Mr. Icahn.”